Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun 23;8(7):388.
doi: 10.3390/nu8070388.

Efficacy of Aloe Vera Supplementation on Prediabetes and Early Non-Treated Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Affiliations
Free PMC article
Review

Efficacy of Aloe Vera Supplementation on Prediabetes and Early Non-Treated Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Yiyi Zhang et al. Nutrients. .
Free PMC article

Abstract

The aim of this study was to evaluate evidence for the efficacy of aloe vera on managing prediabetes and early non-treated diabetes mellitus. We performed a systematic search of PubMed, Embase, and Cochrane Central Register of Controlled Trials until 28 January 2016. A total of five randomized controlled trials (RCTs) involving 415 participants were included. Compared with the controls, aloe vera supplementation significantly reduced the concentrations of fasting blood glucose (FBG) (p = 0.02; weighed mean difference [WMD]: -30.05 mg/dL; 95% confidence interval [CI]: -54.87 to -5.23 mg/dL), glycosylated hemoglobin A1c (HbA1c) (p < 0.00001; WMD: -0.41%; 95% CI: -0.55% to -0.27%), triglyceride (p = 0.0001), total cholesterol (TC) (p < 0.00001), and low density lipoprotein-cholesterol (LDL-C) (p < 0.00001). Aloe vera was superior to placebo in increasing serum high density lipoprotein-cholesterol (HDL-C) levels (p = 0.04). Only one adverse event was reported. The evidence from RCTs showed that aloe vera might effectively reduce the levels of FBG, HbA1c, triglyceride, TC and LDL-C, and increase the levels of HDL-C on prediabetes and early non-treated diabetic patients. Limited evidence exists about the safety of aloe vera. Given the small number and poor quality of RCTs included in the meta-analysis, these results are inconclusive. A large-scale, well-designed RCT is needed to further address this issue.

Keywords: aloe vera; meta-analysis; prediabetes; randomized controlled trials.

Figures

Figure 1
Figure 1
Flow diagram for study identification.
Figure 2
Figure 2
Forest plot of studies that evaluated the effect of aloe vera on primary outcomes compared with placebo. Each block represents a study. Size of square is proportional to the precision of the estimate. Each square represents the weighted mean difference (WMD) or standardized mean difference (SMD) for each study with 95% confidence interval (CI) indicated by horizontal line. FBG, fasting blood glucose; HbA1c, hemoglobin A1c.
Figure 2
Figure 2
Forest plot of studies that evaluated the effect of aloe vera on primary outcomes compared with placebo. Each block represents a study. Size of square is proportional to the precision of the estimate. Each square represents the weighted mean difference (WMD) or standardized mean difference (SMD) for each study with 95% confidence interval (CI) indicated by horizontal line. FBG, fasting blood glucose; HbA1c, hemoglobin A1c.
Figure 3
Figure 3
Forest plot of studies that evaluated the effect of aloe vera on secondary outcomes compared with placebo. See Figure 2 for the legend of symbols used. TC, total cholesterol; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol.
Figure 3
Figure 3
Forest plot of studies that evaluated the effect of aloe vera on secondary outcomes compared with placebo. See Figure 2 for the legend of symbols used. TC, total cholesterol; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol.

Similar articles

See all similar articles

Cited by 2 articles

References

    1. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053. doi: 10.2337/diacare.27.5.1047. - DOI - PubMed
    1. American Diabetes Association Standards of medical care in diabetes-2014. Diabetes Care. 2015;38(Suppl. S1):S31–S33. - PubMed
    1. Tabák A.G., Herder C., Rathmann W., Brunner E.J., Kivimäki M. Prediabetes: A high-risk state for diabetes development. Lancet. 2012;379:2279–2290. doi: 10.1016/S0140-6736(12)60283-9. - DOI - PMC - PubMed
    1. American Diabetes Association Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31:596–615. - PubMed
    1. Hou Q., Li Y., Li L., Cheng G., Sun X., Li S., Tian H. The Metabolic Effects of Oats Intake in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Nutrients. 2015;7:10369–10387. doi: 10.3390/nu7125536. - DOI - PMC - PubMed
Feedback